The global allergy diagnostic market is projected to grow from USD 6.80 billion in 2026 to USD 10.77 billion by 2031, registering a CAGR of 9.6% during the forecast period. The market is expanding steadily due to the increasing prevalence of allergic diseases, growing awareness of early diagnosis, and continuous advancements in laboratory-based diagnostic technologies. As allergies become more common across all age groups, healthcare providers are increasingly relying on accurate diagnostic tools to identify allergens and deliver personalised treatment strategies.
The transition from traditional in vivo allergy testing to advanced in vitro diagnostics, coupled with the adoption of molecular diagnostics and automated laboratory systems, is further supporting market growth.
Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=232871701
Rising Burden of Allergic Diseases Drives Market Expansion
The increasing global prevalence of allergic disorders is one of the primary factors driving the allergy diagnostic market.
Conditions such as:
- Allergic rhinitis
- Asthma
- Atopic dermatitis
- Food allergies
- Drug allergies
are becoming more common due to a combination of genetic predisposition and environmental influences, including urbanisation, air pollution, climate change, and changing lifestyle patterns.
Symptoms such as sneezing, wheezing, itching, skin irritation, and digestive discomfort have increased demand for rapid and accurate allergy diagnosis, enabling clinicians to identify specific allergens and recommend targeted treatment plans.
Growing Demand for Personalised Allergy Management
Accurate allergy diagnostics play a crucial role in personalised patient care.
Modern diagnostic tests help clinicians:
- Identify allergen-specific IgE antibodies
- Differentiate between multiple allergens
- Guide allergen avoidance strategies
- Support allergen immunotherapy
- Optimise pharmacological treatment
For example, identifying sensitivity to specific pollens or food allergens enables physicians to develop tailored treatment plans that improve patient outcomes while reducing unnecessary dietary restrictions and medication use.
Increasing Food Allergy Cases Highlight Need for Early Diagnosis
Food allergies are becoming increasingly common, particularly among children.
Paediatric healthcare providers are placing greater emphasis on early allergy testing to prevent severe allergic reactions while avoiding unnecessary long-term elimination diets that may contribute to nutritional deficiencies.
Early diagnosis allows healthcare professionals to:
- Confirm true food allergies
- Reduce unnecessary dietary restrictions
- Improve nutritional management
- Enhance quality of life
- Prevent life-threatening allergic reactions
This growing need for paediatric allergy testing continues to create significant opportunities for diagnostic laboratories and healthcare providers.
Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=232871701
Molecular Diagnostics and Comprehensive Testing Panels Gain Momentum
Healthcare providers are increasingly adopting comprehensive allergy testing panels and molecular diagnostics to improve diagnostic accuracy.
Modern allergy diagnostics offer several advantages, including:
- High analytical sensitivity
- Improved specificity
- Faster laboratory turnaround
- Multiplex allergen testing
- Reduced trial-and-error treatment approaches
The growing use of molecular allergy diagnostics enables clinicians to distinguish between genuine sensitisation and cross-reactivity, resulting in more accurate diagnoses and personalised treatment recommendations.
Laboratory Automation Strengthens Diagnostic Efficiency
Advances in laboratory automation and digital connectivity are transforming allergy diagnostics.
Automated immunoassay systems enable laboratories to:
- Process higher testing volumes
- Improve workflow efficiency
- Reduce manual errors
- Shorten reporting times
- Enhance quality control
These innovations are supporting the increasing demand for allergy testing while helping healthcare systems manage growing patient volumes more efficiently.
Competitive Landscape
The allergy diagnostic market is highly competitive, with global diagnostics companies and regional manufacturers investing heavily in assay development, automation, and laboratory technologies.
Major companies operating in the market include:
- Thermo Fisher Scientific Inc. (US)
- Siemens Healthineers AG (Germany)
- Danaher Corporation (US)
- Minaris Medical America, Inc. (US)
- Omega Diagnostics Group Plc (UK)
- bioMérieux SA (France)
- Romer Labs Division Holding (Austria)
- EUROIMMUN MEDIZINISCHE LABORDIAGNOSTIKA AG (Germany)
- HollisterStier Allergy (US)
- Eurofins Scientific (Luxembourg)
- Stallergenes Greer (UK)
- HOB Biotech Group Corp., Ltd. (China)
- HYCOR Biomedical (US)
- R-Biopharm AG (Germany)
- AESKU.GROUP GmbH (Germany)
- ACON Laboratories, Inc. (US)
- Lincoln Diagnostics, Inc. (US)
- Astra Biotech GmbH (Germany)
- Erba Group (UK)
- Alcit India Pvt. Ltd. (India)
- Biopanda Reagents (UK)
- Bioside S.r.l. (Italy)
- Creative Diagnostic Medicare Pvt. Ltd. (India)
- DST Diagnostische Systeme & Technologien GmbH (Germany)
- Dr. Fooke Laboratorien GmbH (Germany)
These companies continue to strengthen their market positions through product innovation, strategic partnerships, geographic expansion, and investments in laboratory automation.
Company Spotlight
Thermo Fisher Scientific Inc. (US)
Thermo Fisher Scientific is one of the leading companies in the allergy diagnostic market, recognised for its comprehensive allergy testing portfolio.
Its Phadia platform is widely used in hospitals, clinical laboratories, and diagnostic centres for in vitro allergy testing. Serving more than 400,000 customers worldwide, the company supports pharmaceutical and biotechnology firms, hospitals, academic institutions, research organisations, government agencies, and industrial laboratories.
Its extensive global footprint, broad product portfolio, and strong customer base continue to reinforce its leadership position in allergy diagnostics.
Danaher Corporation (US)
Danaher participates in the allergy diagnostics market through its subsidiary Beckman Coulter, which operates within the Core Laboratory Diagnostics segment.
The company provides a wide range of biomedical testing instruments, automated laboratory systems, consumables, and diagnostic assays that support allergy testing alongside broader clinical diagnostics. Beckman Coulter’s solutions enable healthcare providers to diagnose diseases, monitor treatment, and manage chronic conditions across hospitals, outpatient centres, and physician practices.
Siemens Healthineers AG (Germany)
Siemens Healthineers has strengthened its position in allergy diagnostics by expanding its immunodiagnostics portfolio and investing in laboratory automation technologies.
The company has enhanced assay menus, improved analyser throughput, and integrated digital connectivity solutions that streamline laboratory workflows and reduce turnaround times. Strategic partnerships and ongoing research and development have further strengthened its capabilities, supporting the industry’s transition from traditional in vivo allergy testing toward advanced in vitro diagnostic solutions.
Market Ranking
The allergy diagnostic market is highly competitive, with leading companies accounting for more than 35% of the global market share in 2025.
Key market leaders include:
- Thermo Fisher Scientific Inc. (US), recognised for its comprehensive Phadia allergy testing platform and strong global presence.
- Siemens Healthineers AG (Germany), leveraging advanced immunodiagnostic technologies, laboratory automation, and digital workflow solutions.
- Danaher Corporation (US), through Beckman Coulter, providing high-performance laboratory instruments, consumables, and allergy testing solutions.
- Revvity (EUROIMMUN MEDIZINISCHE LABORDIAGNOSTIKA AG) (Germany), offering advanced immunodiagnostic assays and laboratory testing technologies.
- Canon (Minaris Medical America, Inc.) (US), expanding its diagnostic capabilities through innovative laboratory solutions and strategic investments.
Alongside these multinational leaders, numerous regional manufacturers—particularly across China and India—are strengthening their competitive positions by developing affordable immunoassay kits, compact analysers, and diagnostic consumables. Improving healthcare infrastructure, expanding laboratory capacity, and increasing awareness of allergic diseases across emerging economies continue to create significant growth opportunities for both regional and global market participants.
Future Outlook
The global allergy diagnostic market is expected to experience sustained growth through 2031 as allergic diseases continue to rise worldwide. Increasing demand for early and accurate diagnosis, expanding use of molecular diagnostics, advances in laboratory automation, and growing adoption of personalised medicine are expected to drive continued innovation across the industry.
As healthcare providers increasingly shift toward highly sensitive in vitro diagnostic technologies and comprehensive allergy testing panels, the market will play an increasingly important role in improving patient outcomes, supporting targeted therapies, and enhancing the overall management of allergic diseases across diverse healthcare settings.
Get Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=232871701